WO2022181786A1 - 育毛剤 - Google Patents

育毛剤 Download PDF

Info

Publication number
WO2022181786A1
WO2022181786A1 PCT/JP2022/008010 JP2022008010W WO2022181786A1 WO 2022181786 A1 WO2022181786 A1 WO 2022181786A1 JP 2022008010 W JP2022008010 W JP 2022008010W WO 2022181786 A1 WO2022181786 A1 WO 2022181786A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
palmitoyl dipeptide
adenosine
hair restorer
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/008010
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
秀樹 高橋
荘太 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adjuvant Holdings Co Ltd
Original Assignee
Adjuvant Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjuvant Holdings Co Ltd filed Critical Adjuvant Holdings Co Ltd
Priority to JP2023502551A priority Critical patent/JPWO2022181786A1/ja
Priority to CN202280008688.0A priority patent/CN116916882A/zh
Priority to TW111107182A priority patent/TW202302137A/zh
Priority to KR1020237032280A priority patent/KR20230152072A/ko
Priority to US18/278,728 priority patent/US20240139276A1/en
Publication of WO2022181786A1 publication Critical patent/WO2022181786A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596

Definitions

  • the present invention relates to a hair restorer. More specifically, it relates to a hair restorer that is an external preparation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine.
  • Hair growth repeats growth and shedding according to a hair cycle (hair cycle) consisting of a growth phase, a regression phase, and a resting phase.
  • the symptoms of androgenetic alopecia are that the balance of the hair cycle is lost due to some cause, the period of growth period is shortened, the proportion of telogen hair is increased, and the hair becomes vellus (downy hair).
  • Histologically it has been reported that the size of anagen hair follicles is smaller than that of healthy scalp, the development of dermal papilla is poor, and the capillary network surrounding hair follicles is reduced (Non-Patent Document 1).
  • hair restorers that improve hair growth and hair type/hair quality.
  • active ingredients that contribute to the regulation of the hair cycle, which is the life cycle of hair, have been proposed and are being marketed as hair restorers.
  • vascular endothelial growth factor is a growth factor that acts specifically on vascular endothelial cells isolated from the culture medium of pituitary foliculo-stellate (stellate follicle) cells, and promotes the proliferation of vascular endothelial cells. It is known that adenosine promotes the angiogenesis process and enhances vascular permeability. It is clear that when adenosine acts on human dermal papilla cells, it promotes the expression of vascular endothelial growth factor (VEGF). In addition, it has been revealed that the expression of growth factors such as fibroblast growth factor 7 (FGF-7) is promoted (see Patent Document 1, Non-Patent Documents 2-3). .
  • FGF-7 fibroblast growth factor 7
  • Non-Patent Document 4 Adenosine has no reports of major side effects in human clinical trials, and the mechanism of improving thinning hair is not directly related to the regulation of sex hormones. has been proposed and put on the market (Non-Patent Document 4).
  • Palmitoyldipeptide-5-diaminobutyroylhydroxythreonine and palmitoyldipeptide-5-diaminohydroxybutyric acid are known as components of cosmetic raw materials (see Patent Document 2). However, there is no report on the hair growth effect of these ingredients.
  • An object of the present invention is to provide a hair restorer having an excellent hair growth effect.
  • palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid and adenosine are effective ingredients for hair growth.
  • the inventors have found that the activity can be exhibited, and have completed the present invention.
  • a first means of the present invention for solving the above problems is a hair restorer characterized by containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients. is an agent.
  • the second means of the present invention for solving the above problems is characterized by containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid as active ingredients, and is used in combination with adenosine. It is a hair restorer for
  • the third means of the present invention for solving the above problems is characterized by containing adenosine as an active ingredient, which is used in combination with palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid. It is a hair restorer for
  • the fourth means of the present invention for solving the above problems is the hair restorer according to any one of the first to third means of the present invention, which is used for promoting hair shaft growth or hair growth. is.
  • a fifth means of the present invention for solving the above-mentioned problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving hair shaft elongation speed. is.
  • the sixth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving the maximum length of hair shafts. is.
  • the seventh means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the diameter of the hair shaft. be.
  • the eighth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the number of hairs. .
  • the ninth means of the present invention for solving the above problems is the hair restorer according to any one of the first to eighth means of the present invention, which is a solution.
  • a tenth means of the present invention for solving the above problems is the hair restorer according to any one of the first to ninth means of the present invention for hair, bristles, eyebrows and/or eyelashes. is an agent.
  • the eleventh means of the present invention for solving the above problems has a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine into a formulation as active ingredients.
  • a method for producing a hair restorer characterized by:
  • the twelfth means of the present invention for solving the above problems is characterized by comprising a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid into a formulation as active ingredients. , a method for producing a hair restorer for combined use with adenosine.
  • the thirteenth means of the present invention for solving the above problems is palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diamino, characterized by comprising a step of incorporating adenosine as an active ingredient in a formulation.
  • the fourteenth means of the present invention for solving the above problems is a hair restorer comprising a formulation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid and a formulation containing adenosine It is a drug kit.
  • the fifteenth means of the present invention for solving the above problems is a hair restorer for combined use with adenosine, comprising a formulation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid. It's a kit.
  • the sixteenth means of the present invention for solving the above problems is a hair restorer for combined use with palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, which contains an adenosine-containing formulation. It's a kit.
  • the seventeenth means of the present invention for solving the above problems is the administration of palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients, It is a hair growth method.
  • An eighteenth means of the present invention for solving the above problems is a hair restoration method comprising administering the hair restorer according to any one of the first to tenth means of the present invention to a subject. .
  • Another means of the present invention for solving the above problems is a scalp care agent containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients.
  • a scalp care agent containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients. It is a scalp symptom improvement method including administering.
  • palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine are used as active ingredients of a hair restorer, which is an external preparation, so that hair, pubic hair, eyebrows and /
  • a hair restorer which is an external preparation, so that hair, pubic hair, eyebrows and /
  • an excellent hair restorer and scalp care agent exhibiting the effects of promoting hair shaft growth in eyelashes, improving the speed of hair shaft elongation, improving the maximum length of the hair shaft, increasing the diameter of the hair shaft, and the scalp care effect are provided. becomes.
  • Figure 1 shows a mixture of minoxidil, adenosine, palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyrate, and palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5 diamino in human dermal papilla cells.
  • Fig. 10 is a graph showing changes in VEGF gene expression level due to stimulation with hydroxybutyric acid and adenosine for 72 hours.
  • the active ingredients of the hair restorer and scalp care agent which are external preparations according to the present invention, are palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine (Palm-Lys-Val-Dab-Thr-OH), It consists of Palmitoyl Dipeptide-5 Diaminohydroxybutyrate (Palm-Lys-Val-Dab-OH)) and adenosine.
  • the concentrations of palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, which are active ingredients in the hair restorer and scalp care agent of the present invention, and adenosine are 0.001 to 20% by weight. More specifically, it is 0.005 to 10% by weight.
  • the hair restorer and scalp care agent of the present invention are pharmaceuticals, quasi-drugs, cosmetics including cosmetics for hair, lashes, eyebrows and/or eyelashes, and cosmetics for the scalp, and ointments, cataplasms, liniments, lotions, and liquids for external use. , dusting agents, creams, gels, milky lotions, hair tonics, hair sprays, microneedles, etc., but not limited to these.
  • the hair restorer and scalp care agent of the present invention can be produced through a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine as active ingredients.
  • the hair restorer and scalp care agent for combined use with adenosine of the present invention undergoes a step of containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid as active ingredients, , palmitoyldipeptide-5-diaminobutyroylhydroxythreonine and palmitoyldipeptide-5-diaminohydroxybutyric acid to be used in combination with a hair restorer and a scalp care agent can be produced through a step of incorporating adenosine as an active ingredient. Furthermore, in addition to the above steps, if desired, a step of adding additives for formulation may be added.
  • the dosage form of these formulations is , may be the same dosage form or a combination of different dosage forms, and may be provided as a kit for providing formulations of those dosage forms.
  • Components of these additives include, for example, excipients, stabilizers, flavoring agents, bases, dispersants, diluents, anionic surfactants, amphoteric surfactants, nonionic surfactants, cationic surfactants, Active agents, anionic polymers, nonionic polymers, ethylene oxide/propylene oxide block copolymers, alcohols, emulsifiers, percutaneous absorption enhancers, pH adjusters, preservatives, coloring agents, oils and fats, mineral oils, etc.
  • the hair restorer and scalp care agent of the present invention may further contain known ingredients having effects such as hair growth, hair restoration, and hair nourishing.
  • the dosage of the active ingredient per administration of the hair restorer and scalp care agent in the means of the present invention can be adjusted so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
  • the dosage can be, for example, 0.005 to 200 mg, specifically 0.05 to 100 mg, and more specifically 0.5 to 10 mg.
  • the administration frequency of the hair restorer and scalp care agent of the present invention can be once or multiple times so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
  • the frequency of administration of the hair restorer and scalp care agent of the present invention can be, for example, 1 to 6 times per day. Specifically, it can be 1 to 3 times per day, more specifically 1 to 2 times per day.
  • the hair restorer and scalp care agent of the present invention relate to promotion of hair shaft growth, hair growth and prevention of hair loss, preferably promotion of hair shaft growth and hair growth.
  • promoting hair shaft growth means improving the hair shaft elongation speed, improving the maximum hair shaft length, and/or increasing the hair shaft diameter.
  • hair growth means that hair growth has stopped at a site where hair does not grow (the hair shaft does not protrude from the epidermis) or where the number of hairs is small, or the ability to grow hair is reduced. It means to promote the growth of new hairs from the pores to increase the number of hairs, in particular, to shorten the resting phase in the hair cycle and / or to restart the stopped hair cycle. .
  • having a hair shaft growth promoting effect means acting favorably on hair shaft growth promotion, and the property showing the hair shaft growth promoting effect is referred to as “hair shaft growth promoting activity”.
  • has a hair growth effect means that it acts favorably on hair growth, and the property showing the hair growth effect is referred to as “hair growth promoting activity”.
  • hair loss refers to a phenomenon in which hair shafts fall out of pores, and specifically refers to an increase in inhibitory cytokines that inhibit cell proliferation and cell death. Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
  • anti-hair loss activity Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
  • the term “has an anti-hair loss effect” means that the number of hair shafts falling out from pores is reduced through the inhibition or reduction of inhibitory cytokines and the suppression of cell death. It is a physiological phenomenon that is different from the attribute that indicates the hair effect.
  • scalingp symptoms means symptoms such as dandruff, rough skin, dry scalp, erythema, itching, and pimples.
  • scaling symptom improvement means suppression or improvement of dandruff, rough skin, dryness of the scalp, erythema, itching, pimples, and the like.
  • the hair restorer of the present invention can be used to improve the elongation speed of hair shafts or the maximum length of hair shafts. Then, the hair shaft elongation speed can be improved, for example, by about 110% at maximum, and specifically by about 25 to 110%, compared to the hair shaft elongation speed in the standard data of the hair cycle. More specifically, it can be improved by about 33 to 110%.
  • the maximum length of the hair shaft can be improved, for example, by about 49% at maximum, specifically by about 1 to 49%, compared to the maximum length of the hair shaft in the standard data of the hair cycle. More specifically, it can be improved by about 2 to 49%.
  • the hair restorer of the present invention can be used to increase the diameter of hair shafts.
  • the hair restorer of the present invention causes new hairs to grow from pores where hair growth has stopped (no hair shafts protrude from the epidermis) or where there are few hairs, or where hair growth ability has decreased. It can be used to promote hair growth to increase hair number, and in particular can be used to shorten the telogen phase in the hair cycle and/or to restart stopped hair cycles.
  • the hair restorer and scalp care agent of the present invention can be used not only for humans but also for animals such as livestock and pets.
  • an external preparation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and adenosine is administered to subjects including humans and animals such as livestock and pets.
  • a hair growth method and a scalp condition ameliorating method are provided, comprising:
  • the VEGF gene is expressed in dermal papilla cells and exhibits effects such as promotion of hair shaft growth, improvement in hair shaft elongation speed, improvement in maximum hair shaft length, and increase in hair shaft diameter in hair, hair, eyebrows and/or eyelashes. is said to contribute to Therefore, human dermal papilla cells were used to evaluate the enhancement of VEGF gene expression in each component.
  • Human dermal papilla cells and medium Human dermal papilla cells (catalog number: CA60205a, Caucasian, 29-year-old male, Toyobo Co., Ltd. (Japan)) were purchased and prepared as described in the protocol. We maintained and cultured the cells and performed test evaluations.
  • the FastGene RNA Basic Kit (catalog number: FG-80250, Nippon Genetics Co., Ltd. (Japan)) was used to collect total RNA from the cells.
  • the FastGene RNA binding column was transferred to a new collection tube and set, 700 ⁇ L of washing buffer RW2 was added to the FastGene RNA binding column, and centrifuged at 10000 g for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube, set, and centrifuged at 15000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube and set, 50 ⁇ L of elution buffer RE was added to the center of the FastGene RNA binding column membrane, and centrifuged at 10000 g for 1 minute at room temperature to collect the purified RNA.
  • the concentration of the collected RNA was measured with NanoDrop Lite (catalog number: ND-LITE, Thermo Fisher Scientific Co., Ltd.) and stored at -80°C until the next cDNA conversion.
  • FastGene scriptase II cDNA synthesis 5x Ready Mix (catalog number: NE-LS64, Nippon Genetics Co., Ltd. (Japan)) was used for cDNA synthesis.
  • the total RNA produced in a new tube was diluted with RNase-Free Water so that the concentration was 20 ng/mL, and 4 ⁇ L of FastGene scriptase II cDNA synthesis 5 ⁇ Ready Mix was added to 16 ⁇ L of this sample solution and vortexed.
  • a MiniAmp thermal cycler Thermo Fisher Scientific Co., Ltd.
  • the cDNA synthesized by the above method was used for real-time PCR.
  • Add each cDNA template dilution to a predetermined well of a 96-well plate, add THUNDERBIRD SYBR qPCR Mix (catalog number: QPS-201, Toyobo Co., Ltd. (Japan)) and primers, mix, and mix with QuantStudio 7 Flex Real - Gene expression was analyzed with Time PCR System (catalog number: 4485693, Thermo Fisher Scientific Co., Ltd.).
  • As a PCR reaction 40 cycles of 95°C for 5 seconds, 60°C for 30 seconds, and 72°C for 30 seconds were performed.
  • VEGF gene-specific primers used in the test and the GAPDH gene-specific primers used as internal standards are shown below.
  • Primer for detecting VEGF gene expression Forward direction: atcttcaagccatcctgtgtgc (SEQ ID NO: 1) Reverse: caaggcccacagggattttc (SEQ ID NO: 2)
  • Primer for detecting GAPDH gene expression Forward direction: catccctgcctctactggcgctgcc (SEQ ID NO: 3)
  • the relative expression level of each gene was calculated as follows.
  • the Ct value (PCR cycle number) was calculated from the intersection of the amplification curve of each gene and the threshold line.
  • the value obtained by dividing the Ct value of the target gene by the Ct value of the internal standard GAPDH gene is the relative expression level.
  • a mixture of palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid enhances the expression of VEGF gene in dermal papilla cells more than when adenosine acts, , Promotes hair shaft growth in eyebrows and/or eyelashes, improves hair shaft elongation speed, improves maximum hair shaft length, and increases hair shaft diameter.
  • a mixture of palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyrate combined with adenosine increased the expression of the VEGF gene in dermal papilla cells by palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and Compared to a mixture of palmitoyl dipeptide-5 diaminohydroxybutyric acid or adenosine as an active ingredient, the expression of the VEGF gene in dermal papilla cells is significantly enhanced, and the hair, bristles, eyebrows and / or eyelashes It was confirmed that it is useful as an active ingredient of a hair restorer that exhibits the effects of promoting hair shaft growth, improving the rate of elongation of the hair shaft, improving the maximum length of the hair shaft, and further increasing the diameter of the hair shaft.
  • palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid and adenosine are used as active ingredients of the hair restorer, so that hair, pubic hair, eyebrows and/or eyelashes are It is possible to provide a new hair restorer and a scalp care agent that exhibit the effect of promoting the growth of the hair shaft, the effect of improving the hair shaft elongation speed, the effect of improving the maximum length of the hair shaft, and the scalp care effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2022/008010 2021-02-26 2022-02-25 育毛剤 Ceased WO2022181786A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2023502551A JPWO2022181786A1 (https=) 2021-02-26 2022-02-25
CN202280008688.0A CN116916882A (zh) 2021-02-26 2022-02-25 育毛剂
TW111107182A TW202302137A (zh) 2021-02-26 2022-02-25 育毛劑
KR1020237032280A KR20230152072A (ko) 2021-02-26 2022-02-25 육모제
US18/278,728 US20240139276A1 (en) 2021-02-26 2022-02-25 Hair growth agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-031138 2021-02-26
JP2021031138 2021-02-26

Publications (1)

Publication Number Publication Date
WO2022181786A1 true WO2022181786A1 (ja) 2022-09-01

Family

ID=83047567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/008010 Ceased WO2022181786A1 (ja) 2021-02-26 2022-02-25 育毛剤

Country Status (6)

Country Link
US (1) US20240139276A1 (https=)
JP (1) JPWO2022181786A1 (https=)
KR (1) KR20230152072A (https=)
CN (1) CN116916882A (https=)
TW (1) TW202302137A (https=)
WO (1) WO2022181786A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240023618A (ko) * 2021-06-19 2024-02-22 가부시키가이샤 아쥬반트 홀딩스 육모제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012126671A (ja) * 2010-12-15 2012-07-05 Ltt Bio-Pharma Co Ltd 育毛剤
JP2013151480A (ja) * 2011-12-26 2013-08-08 Rohto Pharmaceutical Co Ltd 外用組成物の安定化方法
CN111329779A (zh) * 2020-03-23 2020-06-26 烟台中科恩吉科创新产业园管理有限公司 一种促毛发增长的活性肽组合物及其应用
WO2021075219A1 (ja) * 2019-10-18 2021-04-22 株式会社アジュバンコスメジャパン 育毛剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1231000A (en) * 1998-10-26 2000-05-15 University Of Massachusetts Treatment of skin with adenosine or adenosine analog
US20070299032A1 (en) 2003-11-11 2007-12-27 Shiseido Company, Ltd. Method and Composition for Thickening Hair
BRPI0621609B1 (pt) 2006-04-28 2017-12-19 Dsm Ip Assets B.V. Composition, non-therapeutic use of the composition and compounds
JP5754053B2 (ja) * 2009-04-22 2015-07-22 ディーエスエム アイピー アセッツ ビー．ブイ． 新規な組成物
CN101716130A (zh) * 2009-12-07 2010-06-02 广东拉芳日化有限公司 一种含有水包油纳米包裹活性成份的头发护理用品组合物
WO2015157692A1 (en) * 2014-04-10 2015-10-15 Cgtn C.V. Skin care composition comprising plant extracts
CN110368397A (zh) * 2019-08-21 2019-10-25 上海棠美生物科技有限公司 一种防止脱发促进毛发生长的外用组合物及其制备方法
CN110772446B (zh) * 2019-12-19 2023-08-22 深圳市维琪科技股份有限公司 一种油包水体系皮肤修复多肽组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012126671A (ja) * 2010-12-15 2012-07-05 Ltt Bio-Pharma Co Ltd 育毛剤
JP2013151480A (ja) * 2011-12-26 2013-08-08 Rohto Pharmaceutical Co Ltd 外用組成物の安定化方法
WO2021075219A1 (ja) * 2019-10-18 2021-04-22 株式会社アジュバンコスメジャパン 育毛剤
CN111329779A (zh) * 2020-03-23 2020-06-26 烟台中科恩吉科创新产业园管理有限公司 一种促毛发增长的活性肽组合物及其应用

Also Published As

Publication number Publication date
JPWO2022181786A1 (https=) 2022-09-01
KR20230152072A (ko) 2023-11-02
TW202302137A (zh) 2023-01-16
US20240139276A1 (en) 2024-05-02
CN116916882A (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
JP4195763B2 (ja) 毛髪保護作用と毛髪減損の予防性並びにアンドロゲン性脱毛症の外因作用とその結果もたらされる毛髪減損の低下性において、改善された性質を有するヘアローション
WO2022265053A1 (ja) 育毛剤
EP2119431B1 (fr) Composition contenant l'association de madécassoside et/ou de terminoloside et d'une arginine et/ou l'un de ses sels et/ou l'un de ses dérivés; utilisation de l'association pour induire et/ou stimuler la croissance de ces fibres kératiniques humaines et/ou freiner leur chute.
WO2022181786A1 (ja) 育毛剤
WO2022265054A1 (ja) 育毛剤
WO2022265052A1 (ja) 育毛剤
FR2984129A1 (fr) Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
WO2022181785A1 (ja) 育毛剤
JP7291333B2 (ja) 育毛剤
HK40102132A (zh) 育毛剂
KR102035812B1 (ko) 모발 성장 촉진제
HK40102133A (zh) 育毛剂
HK40092879A (zh) 育毛剂
HK40101945A (zh) 育毛剂
US10543227B2 (en) Hair growth composition
JP2004331664A (ja) ピリミジン−ｎ−オキシド誘導体を含有する毛髪用組成物、ケラチン繊維の成長を刺激し及び／又は抜毛を減少させるためのその使用
HK40092880A (zh) 育毛剂
WO2025084438A1 (ja) 硫酸転移酵素産生促進剤および硫酸転移酵素活性促進剤
JP2023025132A (ja) スカルプケア剤
WO2022124212A1 (ja) 毛髪改善のための組成物
EP2465581B1 (en) Non-therapeutic use of a composition for promoting hair growth
FR3156651A1 (fr) Composition cosmétique comprenant du niacinamide et un gingérol pour le traitement de la chute des cheveux
FR3156650A1 (fr) Composition cosmétique comprenant un composé apte à inhiber l’enzyme FIH-1 et un composé apte à inhiber l’enzyme PHD2 pour le traitement de la chute5 des cheveux
JP2001048756A (ja) 養毛化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22759820

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023502551

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202280008688.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12023552322

Country of ref document: PH

Ref document number: 18278728

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20237032280

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22759820

Country of ref document: EP

Kind code of ref document: A1